5,0
22. Apr. 2026
Aktueller Mitarbeiter, mehr als 5 Jahre
San Francisco, CA
Empfehlen
CEO-Befürwortung
Geschäftsprognose
Pros
chance to make a bigger impact than at big pharma but not as risky as a small biotech or start up where the company can run out of funding, high pay, flexible hours
Kontras
longer work hours, off-hour calls with different regions depending on the role, experiences can vary by group